Bowen Hanes & Co’s Vertex Pharmaceuticals VRTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $60.5M | Hold |
135,399
| – | – | 1.47% | 34 |
|
|
2026
Q1 | $60.5M | Buy |
135,399
+1,895
| +1% | +$884K | 1.47% | 34 |
|
|
2025
Q4 | $60.5M | Buy |
133,504
+9,070
| +7% | +$3.91M | 1.52% | 30 |
|
|
2025
Q3 | $48.7M | Sell |
124,434
-56,365
| -31% | -$23.6M | 1.22% | 38 |
|
|
2025
Q2 | $80.5M | Buy |
180,799
+1,890
| +1% | +$871K | 2.03% | 15 |
|
|
2025
Q1 | $86.7M | Sell |
178,909
-1,715
| -0.9% | -$799K | 2.41% | 10 |
|
|
2024
Q4 | $72.7M | Buy |
180,624
+1,740
| +1% | +$807K | 1.95% | 17 |
|
|
2024
Q3 | $83.2M | Sell |
178,884
-620
| -0.3% | -$298K | 2.18% | 13 |
|
|
2024
Q2 | $84.1M | Buy |
179,504
+1,730
| +1% | +$751K | 2.33% | 8 |
|
|
2024
Q1 | $74.3M | Buy |
177,774
+3,974
| +2% | +$1.68M | 2.12% | 12 |
|
|
2023
Q4 | $70.7M | Sell |
173,800
-1,600
| -0.9% | -$591K | 2.13% | 12 |
|
|
2023
Q3 | $61M | Buy |
175,400
+2,110
| +1% | +$738K | 2.05% | 10 |
|
|
2023
Q2 | $61M | Sell |
173,290
-1,660
| -0.9% | -$559K | 1.95% | 17 |
|
|
2023
Q1 | $55.1M | Sell |
174,950
-260
| -0.1% | -$78K | 1.89% | 21 |
|
|
2022
Q4 | $50.6M | Sell |
175,210
-5,800
| -3% | -$1.77M | 1.79% | 22 |
|
|
2022
Q3 | $52.4M | Sell |
181,010
-10,515
| -5% | -$3.03M | 2.03% | 14 |
|
|
2022
Q2 | $54M | Sell |
191,525
-1,105
| -0.6% | -$296K | 1.96% | 18 |
|
|
2022
Q1 | $50.3M | Sell |
192,630
-1,490
| -0.8% | -$354K | 1.5% | 27 |
|
|
2021
Q4 | $42.6M | Buy |
194,120
+15,475
| +9% | +$3.01M | 1.2% | 38 |
|
|
2021
Q3 | $32.4M | Buy |
178,645
+28,645
| +19% | +$5.59M | 1% | 43 |
|
|
2021
Q2 | $30.2M | Buy |
150,000
+19,000
| +15% | +$3.97M | 0.92% | 49 |
|
|
2021
Q1 | $28.2M | Hold |
131,000
| – | – | 0.9% | 50 |
|
|
2020
Q4 | $31M | Hold |
131,000
| – | – | 1.03% | 46 |
|
|
2020
Q3 | $35.6M | Hold |
131,000
| – | – | 1.29% | 38 |
|
|
2020
Q2 | $38M | Sell |
131,000
-4,000
| -3% | -$1.08M | 1.53% | 33 |
|
|
2020
Q1 | $32.1M | Hold |
135,000
| – | – | 1.57% | 33 |
|
|
2019
Q4 | $29.6M | Sell |
135,000
-15,000
| -10% | -$3.04M | 1.22% | 45 |
|
|
2019
Q3 | $25.4M | Hold |
150,000
| – | – | 1.08% | 45 |
|
|
2019
Q2 | $27.5M | Hold |
150,000
| – | – | 1.18% | 42 |
|
|
2019
Q1 | $27.6M | Hold |
150,000
| – | – | 1.22% | 44 |
|
|
2018
Q4 | $24.9M | Sell |
150,000
-15,000
| -9% | -$2.6M | 1.25% | 38 |
|
|
2018
Q3 | $31.8M | Hold |
165,000
| – | – | 1.4% | 35 |
|
|
2018
Q2 | $28M | Hold |
165,000
| – | – | 1.31% | 40 |
|
|
2018
Q1 | $26.9M | Hold |
165,000
| – | – | 1.25% | 39 |
|
|
2017
Q4 | $24.7M | Hold |
165,000
| – | – | 1.1% | 45 |
|
|
2017
Q3 | $25.1M | Sell |
165,000
-15,000
| -8% | -$2.26M | 1.18% | 41 |
|
|
2017
Q2 | $23.2M | Hold |
180,000
| – | – | 1.14% | 46 |
|
|
2017
Q1 | $19.7M | Buy |
180,000
+80,000
| +80% | +$7.04M | 0.99% | 55 |
|
|
2016
Q4 | $7.37M | Buy |
+100,000
| New | +$8.14M | 0.4% | 75 |
|
Other funds holding VRTX
Bowen Hanes & Co's VRTX Position: Q2 2026 in Review
Bowen Hanes & Co held its Vertex Pharmaceuticals (VRTX) position steady in Q2 2026 at 135,399 shares worth $60.5M. The position accounts for 1.47% of the portfolio, ranked #34.
Bowen Hanes & Co first reported a position in VRTX in Q4 2016 and has held it in 39 quarters since. The position peaked at $86.7M in Q1 2025. 1,747 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.
- Bowen Hanes & Co held 135,399 shares of Vertex Pharmaceuticals worth $60.5M as of Q2 2026.
- Bowen Hanes & Co left its Vertex Pharmaceuticals share count unchanged in Q2 2026.
- Vertex Pharmaceuticals made up 1.47% of Bowen Hanes & Co's portfolio in Q2 2026, its #34 holding.
- Bowen Hanes & Co first reported a position in Vertex Pharmaceuticals in Q4 2016 and has held it in 39 quarters since.
- Bowen Hanes & Co's Vertex Pharmaceuticals position peaked at $86.7M in Q1 2025.
- 1,747 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.
Based on Bowen Hanes & Co's 13F filing for Q2 2026, filed 13 Aug 2026.